Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEEL-224 in Advanced Solid Tumors
NCT05329103Phase 1Recruiting
- Sponsor
- Peel Therapeutics
- Start
- Jul 2022
- Primary completion
- Oct 2026
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PEEL-224 in solid tumor (3 arms), sponsored by Peel Therapeutics. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jul 2022; status: recruiting.
02
Drugs
PEEL-224
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05329103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329103.